💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Clopidogrel Hydrochloride

CHEMBL6068338 Phase 4 Aprovado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
358.3 g/mol
LogP
—
Phase
4

A hydrochloride salt form of clopidogrel used to prevent blood clots in patients with heart disease or atrial fibrillation. Like other forms of clopidogrel, it reduces platelet aggregation to lower the risk of heart attack and stroke.

Peso Molecular

358,3000 g/mol

TPSA

57,80 Ų

Áreas Terapêuticas

Pancreatic Cancer Cardiovascular Disease Age-Related Macular Degeneration Pain Management Chronic Obstructive Pulmonary Disease Parkinson's Disease Epilepsy Migraine Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Hyperlipidemia Type 2 Diabetes Hypertension Major Depressive Disorder Gout Chronic Pain HIV/AIDS Heart Failure Atrial Fibrillation

Mecanismo de Ação

Irreversibly blocks P2Y12 ADP receptor on platelets.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Irreversibly blocks P2Y12 ADP receptor on platelets.

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1.Cl

                

                

                
                

                    
InChI

                    
InChI=1S/C16H16ClNO2S.ClH/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;/h2-5,7,9,15H,6,8,10H2,1H3;1H/t15-;/m0./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H17Cl2NO2S

                    

                    
                    

                        
HBD / HBA

                        
1 / 4

                    

                    
                    

                        
Ligações Rotacionáveis

                        
4

                    

                    
                    
                    

                        
Átomos Pesados

                        
22

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
A hydrochloride salt form of clopidogrel used to prevent blood clots in patients with heart disease or atrial fibrillation. Like other forms of clopidogrel, it reduces platelet aggregation to lower the risk of heart attack and stroke.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Irreversibly blocks P2Y12 ADP receptor on platelets.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Clopidogrel Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL6068338.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9798860.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.